Koichi Kisanuki

Koichi Kisanuki

Auto-generated profile, based on publicly available information

Koichi Kisanuki

Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
RNRimei Nishimura
Rimei Nishimura
HKHaruka Kato
Haruka Kato
KKKoichi Kisanuki
Koichi Kisanuki
AOAkinori Oh
Akinori Oh
SHShinzo Hiroi
Shinzo Hiroi
YSYukio Shimasaki
Yukio Shimasaki
Objective To determine real-world trends in antidiabetic drug use, and persistence and adherence, in Japanese patients with type 2 diabetes mellitus (T2DM). Design Retrospective evaluation of administrative claims data (2011–2015) using the Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases. Setting Analysis of two administrative claims databases for Japanese patients with T2DM. Participants Adults (aged ≥18 years) with an International Classification of Diseases, 10th Revision code of T2DM and at least one antidiabetic drug prescription. Main outcome measures Treatment patterns in untreated (UT) or previously treated (PT) patients receiving antidiabetic therapy; persistence with treatment at 12 months; adherence to treatment at 12 months. Results 40 908 and 90 421 patients were included from the JMDC and MDV databases, respectively. The most frequently prescribed therapy at the index (first prescription) date was dipeptidyl peptidase-4 inhibitor (DPP-4i) in UT patients (JMDC: 44.0%, MDV: 54.8%) and combination therapy in PT patients (74.6%, 81.1%). Most common combinations were DPP-4i plus: biguanide (BG; 11.4%, 10.9%), sulfonylurea (SU; 8.4%, 11.0%) or BG+SU (7.8%, 9.1%). In UT or PT patients from either database whose index prescription was for any antidiabetic drug class(es) other than DPP-4i, the most frequent add-on or switch was to DPP-4i. 12-month persistence with index monotherapy was highest with DPP-4i and BG. Adherence was high (≥80%) for all monotherapy schedules, except insulin and glucagon-like peptide-1 agonist, and for the five most frequent two-drug and three-drug combinations. Persistence was greater in elderly UT patients and in those receiving ≤5 medications, but comparatively worse in UT patients with ≥3 index antidiabetic drug classes. Conclusions The findings indicate that DPP-4i is the most commonly used antidiabetic drug class in Japanese patients with T2DM, and persistence and adherence to this antidiabetic drug class are high.

25 October 2019 in Drug Safety
Verified
Journal Article
Open access
PDF file
KKKohei Kaku
Kohei Kaku
KKKoichi Kisanuki
Koichi Kisanuki
MSMari Shibata
Mari Shibata
TOTakashi Oohira
Takashi Oohira
The dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin is an oral, antidiabetic treatment that is approved in many countries to treat patients with type 2 diabetes mellitus (T2DM), including the USA, Europe, and Japan. Alogliptin is efficacious both as monotherapy and as add-on/combination therapy with other commonly prescribed T2DM treatments, such as metformin and pioglitazone. Overall, alogliptin is well-tolerated in patients with T2DM, including older patients, those with renal and/or hepatic impairment, and those at high risk of cardiovascular events. There is a low risk of hypoglycemia, weight gain, acute pancreatitis, and gastrointestinal adverse events with alogliptin treatment, as demonstrated in long-term trials (lasting up to 4.5 years) and in a real-world setting. Additionally, alogliptin has a generally favorable or similar safety profile in comparison to other antidiabetic agents (metformin, thiazolidinediones, sulfonylureas, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, α-glucosidase inhibitors, and insulin). However, further evaluation would be required to determine the mechanism and effect of alogliptin on heart failure, bullous pemphigoid, and inflammatory bowel disease. Of note, due to the ethnic diversity in the epidemiology of T2DM, alogliptin has been shown to be more efficacious in Asian patients than in non-Asian patients with T2DM, but with a similar tolerability profile. These data indicate that DPP-4is, including alogliptin, are important treatment options, especially for Asian patients with T2DM, for whom they have potential as a first-line therapy. This benefit-risk assessment aims to place alogliptin within the current armamentarium of T2DM and aid physicians when choosing optimal diabetes treatment for their patients.

21 December 2018 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
RNRimei Nishimura
Rimei Nishimura
HKHaruka Kato
Haruka Kato
KKKoichi Kisanuki
Koichi Kisanuki
AOAkinori Oh
Akinori Oh
YOYoshie Onishi
Yoshie Onishi
YSYukio Shimasaki
Yukio Shimasaki
Objective: To explore treatment patterns, persistence and adherence between fixed-dose combinations (FDC) and two-pill combinations (TPC) of oral antidiabetic drug (OAD) classes in Japanese patients with type 2 diabetes mellitus (T2DM) using administrative claims databases (Japan Medical Data Center [JMDC] and Medical Data Vision [MDV]). Methods: This was a retrospective, longitudinal cohort analysis conducted between 2011 and 2015, in patients with T2DM receiving OADs as FDC or TPC. Outcomes included prescribing patterns, treatment persistence and adherence. Results: Data from 3,474 and 3,066 patients receiving FDC, and 4,325 and 5,192 patients receiving TPC from the JMDC and MDV databases, respectively, were extracted. The most common OAD combination received by over half of all patients was dipeptidyl peptidase-4 inhibitor (DPP-4i) + thiazolidinediones (TZD) (64.1% [JMDC] and 70.5% [MDV]). Overall, 12-month persistence rates were higher in patients receiving FDC compared with TPC (70.4 vs 66.2% [JMDC], 75.6 vs 55.7% [MDV]). In the JMDC population receiving FDC or TPC, persistence rates were highest with DPP-4i schedules (67.5–83.5%). Median time to discontinuation was significantly longer with biguanide + TZD, and DPP-4i + TZD FDC schedules (p < 0.05) than TPC; adherence rates were ≥80% across all antidiabetic drug classes in both database populations. Conclusions: Persistence and adherence to OADs in Japanese patients with T2DM were greater with FDC compared with TPC, which may suggest increased patient satisfaction due to reduced treatment burden. Further studies are warranted to investigate the impact of adherence and persistence of FDC of OADs on glycaemic control.

1 April 2021 in Atherosclerosis
Verified
Journal Article
Closed access
KKKoichi Kisanuki
Koichi Kisanuki
IMIsao Muraki
Isao Muraki
KYKazumasa Yamagishi
Kazumasa Yamagishi
YKYoshihiro Kokubo
Yoshihiro Kokubo
ISIsao Saito
Isao Saito
STShoichiro Tsugane
Shoichiro Tsugane

12 December 2019 in Current Medical Research and Opinion
Verified
Journal Article
Open access
AOAkinori Oh
Akinori Oh
KKKoichi Kisanuki
Koichi Kisanuki
NNNobuhiro Nishigaki
Nobuhiro Nishigaki
YSYukio Shimasaki
Yukio Shimasaki
KSKazuhiko Sakaguchi
Kazuhiko Sakaguchi
TMTakeshi Morimoto
Takeshi Morimoto
Objective: To explore persistence and adherence with once-daily, twice-daily, or once-weekly DPP-4 inhibitors (DPP-4i) in Japanese patients with type 2 diabetes. Methods: This retrospective, longitudinal, observational cohort study used data from the Japanese nationwide hospital-based Medical Data Vision (MDV) administrative claims database. Data were collected for patients given a new DPP-4i prescription between May 2015 and June 2017 with 1-year follow-up until May 2018. Treatment persistence was defined as the total duration of continuous prescription. Adherence to treatment was measured as the proportion of days covered (PDC). Results: A total of 598,419 patients with a prescription for DPP-4i treatment were identified in the MDV database. Of the 39,826 patients who met the inclusion criteria, 82.4% were receiving once-daily DPP-4i, 15.6% twice-daily DPP-4i, and 2.0% once-weekly DPP-4i. Twelve-month persistence rates with once-daily regimens were 66.3% versus 64.7% with twice-daily (p = .1187), and versus 38.8% with once-weekly, regimens (p < .0001) in the overall population (including untreated [UT] and previously treated [PT] patients); 62.8% with once-daily versus 58.3% with twice-daily (p = .0309), and versus 12.3% with once-weekly regimens (p < .0001) in the UT cohort; and 68.6% with once-daily versus 67.9% with twice-daily (p = .5471), and versus 49.1% with once-weekly regimens (p < .0001) in the PT cohort. In the overall population, 97.8% of patients had a mean PDC of 0.97 with once- and twice-daily, and 65.8% of patients had a mean PDC of 0.74 with once-weekly, DPP-4i regimens. Conclusions: Overall, persistence at 12 months was highest in patients receiving once-daily DPP-4i regimens.